Jacob Thaysen: We’re trying to find the CAGR the last three years, which I don’t have in front of me here, but you’re right Mike, we follow this very accurately. And we’re doing – we continue to do very well in this marketplace. We continue to innovate into it. And we have seen – actually, we have taken share over the last period of time. And if you actually compare our calendar two versus competition, would actually see that we are approximately flat in the LC, LCMS space. And I think that stacks up very well versus competition.
Robert McMahon: Yes, hi Brandon, we can get that to you afterwards.
Brandon Couillard: Okay.
Robert McMahon: I can tell you though, if you looked at the LSAG business over the last three years, it’s been averaging 5% CAGR, despite being forecasted to be down this year. And obviously, those are two large businesses.
Brandon Couillard: Okay. And then I guess, two housekeeping questions for you, Bob. You talked about NASD growth in the third quarter? I imagine it might have been up sequentially with Train B coming online and on the CapEx line. You pushed out $200 million you spend in that. Just roll into ’24? There are some projects maybe you decided to defer from the time being – the environment?
Robert McMahon: Yes, it’s a great question. So NASD, we continue to be very pleased with that. We had our first revenue in Q3 from Train B, the first of many more revenues to come from that standpoint, and expect it to continue, and we’re still on track for the numbers that we’ve been talking about through 50-plus for the full year. And in terms of the CapEx, some of that will roll forward, but it’s not – we’re not going to spend that $200 million in ’24 as well. This would be – we have deferred projects being very rational, really focused on revenue-generating programs. And so, I do expect some of that will flow into ’24, but I don’t expect ’24 to have an incremental $200 million show up in the forecast.
Brandon Couillard: Got it. Thank you.
Operator: We’ll go next now to Puneet Souda at Leerink Partners.
Puneet Souda: Hi Mike, Bob. Thanks for taking the questions.
Mike McMullen: Sure.
Puneet Souda: The first one, thanks. So maybe, Bob, could you elaborate a bit on pricing here? I know pricing was a meaningful contributor initially this year. We’re seeing China, obviously, you talked quite a bit about it, and we’re seeing the headline for China deflation. So wondering if you are expecting pricing to maintain there, or do you expect pricing pressure in China continuing? And also, we’re seeing some of the peer sort of bioprocessing companies talking about local competition rising on the less high tech product. And so wondering if you’re seeing that on any of – sort of your product lines as well?
Robert McMahon: Yes. Let me take the second question first. We can compete against the Chinese local competitors each and every day. And nothing has changed from that standpoint. We continue to feel very good about our portfolio, and continue to drive that growth. In regards to pricing across the board, we were slightly better than what we had expected. It was roughly over – a little over 4% for the quarter. And that was driven across all three of the groups. So we continue to drive – positive price across not only our DGG and ACG business, but also our instrumentation and that’s globally. And we expect to be able to continue to demonstrate the value of our instrumentation across the globe. Obviously, in a deflationary environment, that will put a little more pressure on the instrumentation business, particularly in China but we’ve incorporated that into, our forecast and are still on track for positive price contributions, for the full year in excess of 3%.
